Acr is still very cheap based on the axiron deal with eli lilly,not to mention the female testosterone product(luramist),and elanco(eli lilly animal division) stage 3 fda approval which should be extremely close.Acr is starting to look like a satellite of eli lilly waiting to be brought into the fold.The stock should keep firming up from here as it should only be less than 10 months for the fda to give their final approval for axiron.
